Search

Search results

399 results found

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.

Thaçi, Diamant, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, et al. 2023. “Safety and Efficacy of Bimekizumab through 2 Years in Patients With Moderate-to-Severe Plaque Psoriasis: Longer-Term Results from the BE SURE Randomized Controlled Trial and the Open-Label Extension from the BE BRIGHT Trial.”. The British Journal of Dermatology 188 (1): 22-31.

A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.

Palli, Ma Beatrice Alora, Claire Marie Reyes-Habito, Xinaida T Lima, and Alexa B Kimball. 2013. “A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of 3mg Drospirenone/0.02 Mg Ethinyl Estradiol Compared With Placebo in the Treatment of Moderate Truncal Acne Vulgaris.”. Journal of Drugs in Dermatology : JDD 12 (6): 633-7.